How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

4,922 results for

Severe Persistent Asthma

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

81. Masitinib in the Treatment of Patients With Severe Uncontrolled Asthma and Elevated Eosinophil Levels

: February 8, 2019 Sponsor: AB Science Information provided by (Responsible Party): AB Science Study Details Study Description Go to Brief Summary: The purpose of this study is to assess the safety and efficacy of masitinib (6 mg/kg/day) in severe persistent asthma, uncontrolled with high dose of inhaled corticosteroid and with elevated eosinophil levels. Condition or disease Intervention/treatment Phase Asthma Drug: Masitinib Drug: Placebo Phase 3 Detailed Description: Masitinib is a selective tyrosine (...) .: No Keywords provided by AB Science: Severe persistent asthma Eosinophil Tyrosine kinase inhibitor Additional relevant MeSH terms: Layout table for MeSH terms Asthma Bronchial Diseases Respiratory Tract Diseases Lung Diseases, Obstructive Lung Diseases Respiratory Hypersensitivity Hypersensitivity, Immediate Hypersensitivity Immune System Diseases

2018 Clinical Trials

82. Exposure to secondhand smoke and asthma severity among children in Connecticut. Full Text available with Trip Pro

logistic regression models, adjusted for enrollment date, sex, age, race/ethnicity, area of residence, insurance type, family history of asthma, eczema, and exposure to dogs, cats, gas stove, rodents and cockroaches were used to examine the association between self-reported exposure to SHS and clinician-determined asthma severity (mild, moderate, and severe persistent vs. intermittent asthma).Of the 30,163 children with asthma enrolled in Easy Breathing, between 6 months and 18 years old, living in 161 (...) different towns in CT, exposure to SHS was associated with greater asthma severity (adjusted relative risk ratio (aRRR): 1.07 [1.00, 1.15] and aRRR: 1.11 [1.02, 1.22] for mild and moderate persistent asthma, respectively). The odds of Black and Puerto Rican/Hispanic children with asthma being exposed to SHS were twice that of Caucasian children. Though the odds of SHS exposure for publicly insured children with asthma were three times greater than the odds for privately insured children (OR: 3.02

2017 PLoS ONE

83. Further Studies of Unsuspected Emphysema in Non-Smoking Asthmatics with Persistent Expiratory Airflow Obstruction. (Abstract)

Further Studies of Unsuspected Emphysema in Non-Smoking Asthmatics with Persistent Expiratory Airflow Obstruction. Previously, we and other investigators have described reversible loss of lung elastic recoil in patients with acute and persistent, moderate-to-severe, chronic, treated asthma who never smoked, and its adverse effect on maximal expiratory airflow. In four consecutive autopsies, we reported the pathophysiologic mechanism(s) has been unsuspected mild, diffuse, middle and upper lobe (...) centrilobular emphysema.We performed prospective studies (5 to 22 years) in 25 patients (12 female) with chronic asthma, age 55 ± 15 years, who never smoked, with persistent moderate-to-severe expiratory obstruction. Studies included measuring blood eosinophils, IgE, total exhaled nitric oxide (NO), central airway NO flux, peripheral airway/alveolar NO concentration, impulse oscillometry, heliox curves, lung elastic recoil, and high-resolution thin-section (1 mm) lung CT imaging at full inspiration

2017 Chest

84. Correlation of induced sputum eosinophil levels with clinical parameters in mild and moderate persistent asthma in children aged 7-18 years. (Abstract)

Correlation of induced sputum eosinophil levels with clinical parameters in mild and moderate persistent asthma in children aged 7-18 years. Treatment decisions in asthma are currently based on clinical assessment and spirometry. Sputum eosinophil, being a marker of airway inflammation, can serve as a tool for assessing severity and response to treatment in asthma patients.To measure eosinophil percentage in induced sputum in children with asthma and correlate it with clinical asthma (...) parameters.A prospective observational study was performed at tertiary care hospital on 91 children aged 7-18 years with newly diagnosed mild or moderate persistent asthma. Theinduced sputum eosinophil percentage was obtained at the time of enrollment and three months after treatment with inhaled budesonide. Patients were specifically evaluated for five clinical parameters of asthma, i.e., days of acute exacerbations, use of salbutamol as rescue medication, emergency visits, nighttime cough and days

2017 Journal of Asthma

85. Omalizumab Is Equally Effective in Persistent Allergic Oral Corticosteroid-Dependent Asthma Caused by Either Seasonal or Perennial Allergens: A Pilot Study Full Text available with Trip Pro

Omalizumab Is Equally Effective in Persistent Allergic Oral Corticosteroid-Dependent Asthma Caused by Either Seasonal or Perennial Allergens: A Pilot Study Omalizumab is marketed for chronic severe asthma patients who are allergic to perennial allergens. Our purpose was to investigate whether omalizumab is also effective in persistent severe asthma due to seasonal allergens. Thirty patients with oral corticosteroid-dependent asthma were treated with Omalizumab according to the dosing table (...) prednisolone consumption but no differences were detected in the intergroup comparison. Omalizumab offered the same clinical benefits in the two cohorts regardless of whether the asthma was caused by a seasonal or a perennial allergen. These results strongly suggest that allergens are the trigger in chronic asthma but that it is the persistent exposure to IgE that causes the chronicity.

2017 International journal of molecular sciences

86. Efficacy and Safety of PT001 to Placebo and Open-label Spiriva® Respimat® in Subjects With Persistant Asthma

Efficacy and Safety of PT001 to Placebo and Open-label Spiriva® Respimat® in Subjects With Persistant Asthma Efficacy and Safety of PT001 to Placebo and Open-label Spiriva® Respimat® in Subjects With Persistant Asthma - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (...) (100). Please remove one or more studies before adding more. Efficacy and Safety of PT001 to Placebo and Open-label Spiriva® Respimat® in Subjects With Persistant Asthma The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier

2017 Clinical Trials

87. A Study to Assess Jia Wei Yang He Formula as a Plus Therapy in the Treatment of Persistent Asthma

A Study to Assess Jia Wei Yang He Formula as a Plus Therapy in the Treatment of Persistent Asthma A Study to Assess Jia Wei Yang He Formula as a Plus Therapy in the Treatment of Persistent Asthma - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove (...) one or more studies before adding more. A Study to Assess Jia Wei Yang He Formula as a Plus Therapy in the Treatment of Persistent Asthma The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03299322 Recruitment Status

2017 Clinical Trials

88. Clinical Study on Treatment of Chronic Persistent Bronchial Asthma

Clinical Study on Treatment of Chronic Persistent Bronchial Asthma Clinical Study on Treatment of Chronic Persistent Bronchial Asthma - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Clinical Study (...) on Treatment of Chronic Persistent Bronchial Asthma The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03228134 Recruitment Status : Not yet recruiting First Posted : July 24, 2017 Last Update Posted : December 20, 2017 See Sponsor

2017 Clinical Trials

89. Persistent asthma phenotype related with late-onset, high atopy, and low socioeconomic status in school-aged Korean children. Full Text available with Trip Pro

Persistent asthma phenotype related with late-onset, high atopy, and low socioeconomic status in school-aged Korean children. Treatment guidelines for asthma have been established based on asthma severity; there are limitations in the identification of underlying pathophysiology and prediction of prognosis in heterogeneous phenotypes of asthma. Although the complex interactions between environmental and genetic factors affect the development and progression of asthma, studies on asthma (...) , and low socioeconomic status are associated with troublesome persistent asthma phenotype in school-age children. Environmental factors might be implicated in the clinical heterogeneity of asthma. Asthma phenotypes considering diverse factors might be more helpful in the identification of asthma pathogenesis and its prevention.

2017 BMC pulmonary medicine

90. Predictors of emergency department use in children with persistent asthma in metropolitan Atlanta, Georgia. Full Text available with Trip Pro

Predictors of emergency department use in children with persistent asthma in metropolitan Atlanta, Georgia. Racial disparities are evident among children with asthma in the United States, with non-Hispanic black children at particularly high risk for poor asthma outcomes, including frequent emergency department (ED) use for asthma exacerbations.To compare asthma features in non-Hispanic black vs white children in Atlanta, Georgia, and determine what clinical features predict future ED use (...) for asthma.Self-reported black and white children 6 to 17 years of age with persistent asthma treated with controller medications completed medical history questionnaires, lung function testing, aeroallergen sensitization testing, and venipuncture. Medical records were reviewed for asthma-related ED visits for 12 months after the initial study visit.A total of 276 children were enrolled. Black children, compared with white children, resided in more disadvantaged zip code areas and were more likely to have

2017 Asthma & Immunology

91. Clinical predictors of remission and persistence of adult-onset asthma. Full Text available with Trip Pro

(15.9%) experienced asthma remission. Patients with asthma persistence were older, had worse asthma control, required higher doses of inhaled corticosteroids, had more severe airway hyperresponsiveness, more often nasal polyps, and higher levels of blood neutrophils as compared to patients who experienced clinical remission. In a multivariable logistic regression analysis, only moderate to severe bronchial hyperresponsiveness and nasal polyps were independent predictors of asthma persistence (...) Clinical predictors of remission and persistence of adult-onset asthma. Adult-onset asthma is an important but relatively understudied asthma phenotype and little is known about its natural course and prognosis. The remission rate is believed to be low, and it is still obscure which factors predict remission or persistence of the disease.This study sought to determine the remission rate and identify predictors of persistence and remission of adult-onset asthma.Two hundred adult patients

2017 Journal of Allergy and Clinical Immunology

92. Effectiveness of vitamin D3 in severe persistent asthmatic patients: A double blind, randomized, clinical study. Full Text available with Trip Pro

Effectiveness of vitamin D3 in severe persistent asthmatic patients: A double blind, randomized, clinical study. To assess the pulmonary function and quality of life in asthma patients receiving vitamin D3 supplementation with inhaled budesonide and formoterol.This was a double blinded, randomized, comparative study. Patients were recruited as per the study criteria and randomized into two groups: usual care group (n = 69) patients received budesonide (800 μg) with formoterol (24 μg (...) showed statistically significant (P < 0.05) improvement in symptom, impact and total scores.On the basis of our findings, we conclude that supplementation of vitamin D3 is effective in improving the quality of life rather than pulmonary function in severe asthmatics. However, further studies are warranted to substantiate the present findings.

2015 Journal of pharmacology & pharmacotherapeutics Controlled trial quality: uncertain

93. Efficacy and Safety of BI 655066 in Patients With Severe Persistent Asthma.

Efficacy and Safety of BI 655066 in Patients With Severe Persistent Asthma. Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies (...) before adding more. Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02443298 Recruitment Status : Completed First Posted : May 13, 2015 Last Update Posted : September 13, 2018 Sponsor: AbbVie

2015 Clinical Trials

94. Cost-effectiveness of bronchial thermoplasty in commercially-insured patients with poorly controlled, severe, persistent asthma. Full Text available with Trip Pro

Cost-effectiveness of bronchial thermoplasty in commercially-insured patients with poorly controlled, severe, persistent asthma. We examined the cost-effectiveness of treating poorly controlled, severe, persistent asthma patients with bronchial thermoplasty (BT), a novel technology that uses thermal energy to reduce airway smooth muscle mass, with 5-year outcome data demonstrating a durable reduction in asthma exacerbations.We conducted a model-based cost-effectiveness analysis assessing 5-year (...) healthcare utilization, patient quality of life and adverse events.We utilized Markov modeling to estimate the costs and quality-of-life impact of BT compared with high-dose combination therapy among poorly controlled, severe, persistent asthma patients: those requiring high-dose combination therapy and having experienced an asthma exacerbation-related ER visit in the past year.The cost-effectiveness of BT was US$5495 per quality-adjusted life year; and approximately 22% of sensitivity analysis

2015 Expert review of pharmacoeconomics & outcomes research

95. Persistent severe hypereosinophilic asthma is not associated with airway remodeling. Full Text available with Trip Pro

Persistent severe hypereosinophilic asthma is not associated with airway remodeling. Hypereosinophilic asthma (HEA) is considered as a specific severe asthma phenotype. Whether eosinophils have a link with airway remodeling characterized by pathological (thickening of the basement membrane), functional (persistent airflow impairment and decline in lung function) and imaging features (increase airway wall thickness at CT scan) is still debated. In a one year prospective cohort of 142 severe (...) asthma patients (according to IMI), 14 persistent HEA patients (defined by a persistent blood eosinophilia >500/mm(3) at two consecutive visits) were identified and compared with ten patients without any blood eosinophilia during the follow-up period (NEA, blood eosinophilia always <500/mm(3)). Airflow and lung volumes were recorded. Bronchial biopsies obtained at enrollment were stained for eosinophils (EG2) and basement membrane thickness (BM) was quantified. Imaging by CT scan acquisition

2015 Respiratory medicine

96. Randomised, double-blind, placebo-controlled crossover study to investigate different dosing regimens of olodaterol delivered via Respimat(®) in patients with moderate to severe persistent asthma. Full Text available with Trip Pro

Randomised, double-blind, placebo-controlled crossover study to investigate different dosing regimens of olodaterol delivered via Respimat(®) in patients with moderate to severe persistent asthma. A Phase II, multicentre, randomised, double-blind, placebo-controlled, crossover trial comparing the 24-h forced expiratory volume in 1 s (FEV1) time profile after 3 weeks' treatment with once-daily (QD) or twice-daily (BID) olodaterol (at the same total daily dose) versus placebo delivered via (...) Respimat® in patients with moderate to severe asthma.Patients were randomised to different sequences of olodaterol with 2-week washout, either as a total daily dose of 5 μg (5 μg QD [AM] or 2.5 μg BID) or placebo, or 10 μg (10 μg QD [AM] or 5 μg BID) or placebo. Primary end point was FEV1 area under the curve from 0 to 24 h (AUC0-24) response (defined as change from study baseline FEV1) after 3 weeks. Key secondary end points were FEV1 AUC0-12 and AUC12-24 responses.Two hundred and six patients

2015 Respiratory research Controlled trial quality: predicted high

97. Increased numbers of activated group 2 innate lymphoid cells in the airways of patients with severe asthma and persistent airway eosinophilia. Full Text available with Trip Pro

Increased numbers of activated group 2 innate lymphoid cells in the airways of patients with severe asthma and persistent airway eosinophilia. In patients with severe eosinophilic asthma, local maturation rather than systemic recruitment of mature cells might contribute to persistent airway eosinophilia. Group 2 innate lymphoid cells (ILC2s) are a major source of type 2 cytokines (IL-5 and IL-13) and can facilitate eosinophilic inflammatory responses in mouse models of asthma in the absence (...) of CD4+ lymphocytes, eosinophil lineage-committed progenitors (eosinophilopoietic progenitor cells [EoPs]), and mature eosinophils.Significantly greater numbers of total and type 2 cytokine-producing ILC2s were detected in blood and sputum of patients with severe asthma compared to mild asthmatics. In contrast, intracellular cytokine expression by CD4 cells and EoPs within the airways did not differ between the asthmatic groups. In patients with severe asthma, although sputum CD4+ cells were more

2015 Journal of Allergy and Clinical Immunology

98. British guideline on the management of asthma

treatment Severe/life-threatening asthma attack Severe/life-threatening asthma attack ‘Red flags’ and indicators of other diagnoses Prominent systemic features (myalgia, fever, weight loss) Failure to thrive Unexpected clinical findings (eg crackles, clubbing, cyanosis, cardiac disease, monophonic wheeze or stridor) Unexplained clinical findings (eg focal signs, abnormal voice or cry, dysphagia, inspiratory stridor) Persistent non-variable breathlessness Symptoms present from birth or perinatal lung (...) in the Netherlands available to support GPs’ assessment reported that the service agreed with the GPs’ working diagnosis of asthma in 62% of cases, and was able to provide a diagnosis for 95% of the patients in whom GPs were uncertain. 15, 71 329 C Streamlined referral pathways should be developed for tests which are not routinely available in primary care. 3.5 Wheezing in preschool children and the future risk of developing persistent asthma Several factors are associated with a risk of developing persisting

2019 SIGN

99. Dupilumab (asthma) - Benefit assessment according to §35a Social Code Book V

: dupilumab, asthma, benefit assessment Extract of dossier assessment A19-74 Version 1.0 Dupilumab (asthma) 28 November 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - 3 - Table of contents Page List of tables 4 List of abbreviations 5 2 Benefit assessment 6 2.1 Executive summary of the benefit assessment 6 2.2 Research question 10 2.3 Information retrieval and study pool 11 2.4 Research question 1: Adolescents aged 12 to 17 with inadequately controlled severe type 2 inflammation asthma (...) 12 2.4.1 Results on added benefit 13 2.4.2 Probability and extent of added benefit 13 2.4.3 List of included studies 13 2.5 Research question 2: Adults with inadequately controlled severe type 2 inflammation asthma 14 2.5.1 Results on added benefit 20 2.5.2 Probability and extent of added benefit 20 2.5.3 List of included studies 20 2.6 Probability and extent of added benefit – summary 20 References for English extract 22 Extract of dossier assessment A19-74 Version 1.0 Dupilumab (asthma) 28

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

100. Definition, Evaluation, and Treatment of Severe Asthma:

this approach are those who can produce sputum, demonstrate persistent or at least intermittent eosinophilia and have severe asthma with frequent exacerbations. Clinicians should recognize that different choices will be appropriate for different patients. 2B In children with severe asthma, we suggest treatment guided by clinical criteria alone rather than by clinical criteria and sputum eosinophil counts. conditional very low The recommendation not to use sputum eosinophil counts to guide therapy (...) which contribute to asthma symptoms and exacerbations [172]. International ERS/ATS Guidelines on Definition, Evaluation, and Treatment of Severe Asthma • 2013 Page 34 of 112 Evidence for rhinosinusitis has been reported to be as high at 75-80% [10, 173]. Nasal polyps are seen in a small subset of adults. Nasal polyps are unusual in asthmatic children and more often associated with cystic fibrosis and sometimes primary ciliary dyskinesia. Gastroesophageal reflux (GERD) is present in 60-80% [9-11, 33

2013 American Thoracic Society

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>